Plasma Biomarker in Amblyopia Patients

Study Overview
=================
Brief Summary
-----------------
This prospective study aims to observe the predictive effect of peripheral blood plasma biomarker on the outcome of treatment in children with different types of amblyopia. We also investigated the mechanism of neuromodulation in the visual development of amblyopic children.

Official Title
-----------------
Prognostic Value of Plasma Biomarkers Among Patients With Amblyopia

Conditions
-----------------
Amblyopia

Intervention / Treatment
-----------------
* Procedure: standard amblyopia treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with amblyopia 3-12 years of age Able to tolerate amblyopia treatment Agree to be involved in this study and agree to have a follow up visit every 3 months. Exclusion Criteria: Have previous treatment history before Have pathological ocular anomalies known to cause reduced visual acuity Have previous psychiatric, visual or neurological disorders Have eccentric fixation and/or abnormal retinal correspondence Have attention disorder and learning disability that cannot comprehend psychophysical test instructions given and/or consent for themselves

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Strabismic<br> | Procedure: standard amblyopia treatment<br>* amblyopia treatment following international guidelines and genetic tests.<br>* Other names: plasma biomarker test;|
| Anisometropic<br> | Procedure: standard amblyopia treatment<br>* amblyopia treatment following international guidelines and genetic tests.<br>* Other names: plasma biomarker test;|
| Isoametropic<br> | Procedure: standard amblyopia treatment<br>* amblyopia treatment following international guidelines and genetic tests.<br>* Other names: plasma biomarker test;|
| Visual deprivation<br> | Procedure: standard amblyopia treatment<br>* amblyopia treatment following international guidelines and genetic tests.<br>* Other names: plasma biomarker test;|
| Mixed group<br> | Procedure: standard amblyopia treatment<br>* amblyopia treatment following international guidelines and genetic tests.<br>* Other names: plasma biomarker test;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma protein predictor screening for visual acuity improvement following amblyopia therapy using Tandem Mass Tags proteomics | Peripheral blood will be collected prior and after treatment. The plasma will be separated and Tandem Mass Tags will be used for proteomics. We will detect the different expression of plasma protein between successfully treated and untreated amblyopia patients to find biomarkers that predict amblyopia treatment success. Amblyopia treatment success is defined as best corrected visual acuity (BCVA) improvement of 3 or more logMAR lines. | 2 years after including into this clinical trial | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
amblyopia, plasma biomarker, prediction, treatment outcome